TORONTO, March 15, 2016 /CNW/ - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced that Health Canada has approved its application for the generic version of PrKivexa®. This agent is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults.
PrKivexa® had annual sales of approximately $68.4 million in Canada, based on IMS Brogan sales data as of December 2015. PrTeva-Abacavir/Lamivudine is available immediately in pharmacies across Canada. Teva Canada is the first generic supplier of this treatment in Canada.
"Effective treatment options that minimize the viral load of HIV have significantly contributed to Canadians living longer with this virus," said Doug Sommerville, General Manager, Teva Canada Limited. "As the first generic supplier of Abacavir/Lamivudine tablets, we are pleased to support the HIV community with a lower-cost bioequivalent version of this important antiretroviral agent today."
According to the Public Health Agency of Canada, an estimated 75,500 Canadians were living with HIV at the end of 2014.1 While the prevalence rate of HIV infection is 212 per 100,000 people living in Canada, it is estimated that 16,020 people living with HIV remain undiagnosed in 2014.2 Early diagnosis and treatment intervention with antiretroviral therapy provides the best option for significantly improved life expectancy.
About Teva Canada Limited
Teva Canada Limited, headquartered in Toronto, has provided affordable healthcare solutions for 50 years, with nearly 200,0003 prescriptions filled with our products every day. Originally Novopharm Limited, Teva Canada Limited specializes in the development, production and marketing of high-quality generic prescription pharmaceuticals and through our branded division, Teva Canada Innovation, focuses on a diverse line of innovative products in a variety of therapeutic areas. Teva Canada employs more than 1,300 individuals, markets more than 4004 products in Canada and is a subsidiary of Teva Pharmaceutical Industries Ltd., the world's largest generic drug maker. For more information, visit: www.tevacanada.com or www.tevamakesmedicines.ca.
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.
1 Public Health Agency of Canada. Summary: Estimates of HIV Incidence, Prevalence and Proportion Undiagnosed in Canada, 2014. http://www.catie.ca/sites/default/files/2014-HIV-Estimates-in-Canada-EN.pdf. Accessed February 2016
3 IMS Compuscript TRx MAT December 2015
4 IMS CD&H MAT December 2015
SOURCE Teva Canada Limited
Image with caption: "(Pr)Teva-Abacavir/Lamivudine is available as 600 mg/300 mg tablets in bottles of 30 tablets and blisters of 30 tablets. (CNW Group/Teva Canada Limited)". Image available at: http://photos.newswire.ca/images/download/20160315_C9921_PHOTO_EN_44655.jpg
For further information:
Teva Pharmaceutical Industries Ltd.
Sr. Vice President, Global Corporate Reputation